Horizon Pharma Agrees to Acquire Vidara Therapeutics for $660 Million

Horizon Pharma Inc. and Vidara Therapeutics International Ltd. March 19 announced they have a definitive agreement under which Horizon will acquire Vidara through a reverse merger for stock and cash valued at about $660 million.

Horizon is based in Deerfield, Ill., and Vidara is based in Dublin.

Horizon Pharma Plc will be the name of the company, the companies said. Horizon Pharma Plc will be organized under the laws of Ireland with a portfolio of four products marketed primarily in the U.S. The products are Horizon’s Duexis (ibuprofen and famotidine tablets), Vimovo (naproxen and esomeprazole magnesium delayed-release tablets) and Rayos ...